ImmunoGen, Inc.
Mar 1, 2017

ImmunoGen Announces Presentations at AACR Annual Meeting

Nine presentations featuring the Company's leadership in ADCs

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that nine abstracts highlighting the breadth of the Company's expertise in ADCs will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting to be held from April 1-5, 2017 in Washington D.C. The presentations at AACR cover a wide array of ADC innovations, including further advancements to linkers and payloads and novel targets for both solid tumors and hematological malignancies.

"ImmunoGen has an unmatched expertise and understanding of the core components of ADCs and the data being presented at AACR further validate our full spectrum of knowledge and leadership in this space," said Richard Gregory, Ph.D., ImmunoGen's chief scientific officer. "ImmunoGen will be presenting nine abstracts at the conference with preclinical data demonstrating technology advances that will enable us to continue to drive innovation in ADC approaches."

ImmunoGen presentations at AACR relate to:

Platform linker and payload innovations

Title: Comparison of site-specific and lysine-linked indolino-benzodiazepine antibody-drug conjugates (ADCs) - abstract # 75

Title: Bystander activity and in vivo efficacy of a folate receptor α (FRα)-targeting antibody-drug conjugate with a novel peptide linker - abstract # 71

Title: Peptide-cleavable maytansinoid (ADCs) induce high bystander killing leading to improved anti-tumor activity in vivo - abstract # 2186

Title: Antibody-drug conjugates (ADCs) of peptide-linked Indolino-Benzodiazepine (IGN) DNA-alkylator provides improved anti-tumor activity over that of a crosslinker - abstract # 53

Preclinical research focused on novel targets

Title: Novel antibody-drug conjugates targeting ADAM9-expressing solid tumors demonstrate potent preclinical activity - abstract #37

Title: Target validation, antibody discovery and preclinical data supporting ADAM9 as an antibody-drug conjugate therapeutic target for solid tumors - abstract #38

Title: In vitro and in vivo activity of a novel c-Met-targeting antibody-drug conjugate using a DNA-alkylating, indolinobenzodiazepine payload - abstract #45

Preclinical research focused on B-cell targets

Title: A novel CD19-targeting antibody-drug conjugate, huB4-DGN462, shows promising in vitro and in vivo activity in CD19-positive lymphoma models - abstract #2651

Title: Increased internalization and processing of the CD37-targeting antibody-drug conjugate, naratuximab emtansine (IMGN529), in the presence of rituximab leads to enhanced potency in diffuse large B-cell lymphoma models - abstract #1073

Additional information - including presentation schedule and full abstracts - can be found at

About ImmunoGen, Inc.

ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. ImmunoGen's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in Phase¬†1b/2 testing in combination regimens for earlier-stage disease. ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla®, in three other clinical-stage ImmunoGen product candidates, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at

Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.

This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including risks related to preclinical studies and risks related to new technologies. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended June 30, 2016 and other reports filed with the Securities and Exchange Commission.

For ImmunoGen Investors
ImmunoGen, Inc.
Sarah Kiely, 781-895-0600
For ImmunoGen Media
FTI Consulting, Inc.
Robert Stanislaro, 212-850-5657

Source: ImmunoGen, Inc.

News Provided by Acquire Media